Friday, October 22, 2010

News:NH Man Indicted for Attempted Liver Transplant Scam

,
..
SUMMARY: Results from the INFORM-1 trial, which evaluated 2 experimental agents that target different steps of the hepatitis C virus (HCV) lifecycle, showed that a combination of direct-acting drugs can suppress viral replication without interferon or ribavirin.
.
SUMMARY: HIV positive women with chronic hepatitis C virus (HCV) coinfection experienced side effects of interferon-based therapy that were similar to those of coinfected men, but women developed these side effects sooner and were more likely to discontinue anti-HCV therapy or lower their doses for this reason, according to a study described in the October 1, 2010 Journal of Acquired Immune Deficiency Syndromes.
,
Oct 23
Victoria Police have excecuted search warrants on the home and workplace of Dr James Latham Peters, the doctor suspected of infecting 35 women with hepatitis C. Detectives will search for documents and evidence at his home in Melbourne's East and at the Croydon Day Surgery where he worked from 2006 until late last year
.
NH Man Indicted for Attempted Liver Transplant Scam
By News 13
Story Created: Oct 22, 2010 at 6:48 AM EDT
24-year-old Nathan Hughes of New Hampshire is facing theft by deception charges after police say he tried to swindle an elderly widow from Maine out of $35,000 by telling her he needed a liver transplant.
.
Karten said Montefiore was negligent, and now Hailey is suffering. She’s on a cocktail of AZT medication, used to treat HIV, while the other worry is hepatitis. At this point, nothing can be ruled out.
.
UCSF scientists have received two grants from the California Institute for Regenerative Medicine to refine their human embryonic stem cell-based strategies for treating neurological diseases and liver failure.
“Previous studies have shown that human embryonic stem cell-derived hepatocytes can provide liver function in rodents,” says Willenbring. “We will be seeking to produce human liver cells that stand the test of curing a mouse model of human liver failure, with an eye toward clinical application.”
..
Friday, October 22, 2010
Hershey, Pa. -- A more personalized treatment for people with a type of metastatic liver cancer -- hepatocellular carcinoma -- may be possible by targeting the protein c-Met, according to Penn State College of Medicine researchers. Hepatocellular carcinoma (HCC) is the number three cause of cancer deaths in the world.
.
Scientists studying these diseases have sought a research animal with both human liver cells and a human immune system. But this raises a conundrum: Engineering mice with human liver cells requires annihilation of the mouse immune system so that the foreign cells are not rejected, but the detrimental effects of both hepatitis B and C (HBV and HCV)—cirrhosis, scarring and even liver cancer—stem from the immune response against the virus.
.
Related programs facing cuts include prison clinics, which would stop providing over-the-counter drugs like aspirin, and would also cease giving inmates a 10-day supply of their prescription drugs upon release. Inmate dental and mental health services could be reduced, and routine HIV and Hepatitis C testing would also be suspended.
.
New Virus 'Jumps' From Monkey to Scientist, Causing Serious Illness
Adenovirus strain is under study but experts say there's no immediate cause for alarm
FRIDAY, Oct. 22 (HealthDay News) -- A never-before detected strain of virus that killed more than one-third of a monkey colony at a U.S. lab appears to have 'jumped' from the animals to sicken a human scientist, researchers report
.
Now, liver transplant is affordable - The Times of India
Now, liver transplant is affordablePratibha Masand, TNN, Oct 21, 2010,
12.42am MUMBAI: When 27-year-old Ulhas Chowdhary walked out of KEM Hospital on Tuesday afternoon, it was a mega-moment for the city's premier medical school. Chowdhary is the first patient on whom the institute conducted a liver transplant and, in the process, showed the country that transplants can indeed be affordable.
.
Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide. Its product pipeline includes Telaprevir (VX-950), a Phase III clinical trial product for the treatment of hepatitis C virus (HCV) infection; VX-222, a Phase IIa clinical trial product targeting HCV infection; and VX-985 and VX-759, which are in Phase I clinical trials for the treatment of HCV infection.
..
By Kristina Fiore, Staff Writer, MedPage TodayPublished:
October 22, 2010
Reviewed by Zalman S. Agus, MD; Emeritus Professor University of Pennsylvania School of Medicine andDorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner
..
SAN ANTONIO -- Even in the absence of cirrhosis and fatty liver, obese patients may still be at increased risk for liver cancer, researchers said here.
.
VANCOUVER -- This exclusive press conference coverage focuses on ways to identify more of the estimated quarter million people in the U.S. who have HIV but don't know it. Featured research points to Hispanics and prison inmates as targets and the EHR as a tool to prompt testing.
.
In a report published on October 1, 2010 in the journal Hepatology (online), an expert panel of nationally recognized pediatric liver specialists convened by the Hepatitis B Foundation established the first national...
Posted by at
File Under

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)